Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Does ifosfamide affect gonadal function?

Denise Williams1, P M Crofton, Gill Levitt

  • 1Department of Paediatric Oncology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. denise.williams@addenbrookes.nhs.uks

Pediatric Blood & Cancer
|November 2, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<i>LRP5</i>-related primary osteoporosis: phenotypic spectrum and treatment response to zoledronic acid.

Journal of pediatric endocrinology & metabolism : JPEM·2026
Same author

International Guideline Harmonization Group Recommendations for Breast Cancer Surveillance in Childhood, Adolescent, and Young Adult Cancer Survivors After Anthracyclines.

JCO oncology practice·2026
Same author

Insights into KIF11 pathogenesis in microcephaly-lymphedema-chorioretinopathy syndrome from a lymphatic perspective.

JCI insight·2025
Same author

Barriers and facilitators associated with long-term follow-up care for childhood, adolescent, and young adult cancer survivors: a systematic review.

BMC health services research·2025
Same author

Health-care transitions for young people living beyond childhood and adolescent cancer: recommendations from the EU-CAYAS-NET consortium.

The Lancet. Oncology·2025
Same author

Gonadal function in males with WFS1 spectrum disorder (Wolfram syndrome)-A European cohort perspective.

Andrology·2025
Same journal

Comment on: "The Efficacy and Safety of Bevacizumab/Irinotecan/Temozolomide (BIT) for Relapsed/Refractory Neuroblastoma: The UK Children's Cancer and Leukaemia Group Experience"-The Evolving Role of the BIT Regimen.

Pediatric blood & cancer·2026
Same journal

Extramedullary Intradural Spinal Tumor in an Infant With Neurocutaneous Melanosis.

Pediatric blood & cancer·2026
Same journal

The Role of Hematopoietic Cell Transplantation in Ataxia-Telangiectasia.

Pediatric blood & cancer·2026
Same journal

Pediatric T-Lymphoblastic Lymphoma With T(9;17) and MIR142HG::NOTCH1 Fusion Successfully Treated by Allogeneic Hematopoietic Stem Cell Transplantation in First Complete Remission.

Pediatric blood & cancer·2026
Same journal

Reply to: Comment on: Investigating Biomarkers for Inborn Errors of Immunity in a Prospective Study of Patients With Autoimmune Cytopenia.

Pediatric blood & cancer·2026
Same journal

Comment on: Investigating Biomarkers for Inborn Errors of Immunity in a Prospective Study of Patients With Autoimmune Cytopenia.

Pediatric blood & cancer·2026
See all related articles

Ifosfamide can cause male infertility, especially at higher doses. Females may experience reduced ovarian reserve, potentially impacting fertility and leading to early menopause.

Area of Science:

  • Oncology
  • Reproductive Endocrinology
  • Pediatric Oncology

Background:

  • Cancer therapies, including ifosfamide, can lead to long-term gonadal dysfunction and infertility.
  • Evidence linking ifosfamide to gonadal toxicity is limited.

Purpose of the Study:

  • To evaluate the potential for ifosfamide to cause gonadal dysfunction in patients treated for sarcoma.
  • To assess pubertal development, reproductive hormone levels, and fertility outcomes in male and female patients.

Main Methods:

  • Assessed pubertal development, menstrual history (females), and semen analysis (males).
  • Measured serum gonadotrophins, inhibin B, and anti-Mullerian hormone (AMH) for biochemical evaluation.
  • Included patients treated with ifosfamide as the sole potential gonadotoxic agent.

Related Experiment Videos

Main Results:

  • Males treated with ifosfamide doses >60 g/m(2) showed subfertility (two-thirds), elevated FSH (31%), and decreased inhibin B (50%), indicating germ cell failure.
  • Females exhibited normal pubertal development and menses, but lower AMH levels suggest reduced ovarian reserve.
  • No gonadal dysfunction was observed at ifosfamide doses <60 g/m(2) in males.

Conclusions:

  • Males are more susceptible to ifosfamide-induced gonadotoxicity than females.
  • A potential dose threshold for male subfertility exists below 60 g/m(2).
  • Ifosfamide may reduce ovarian reserve in females, potentially leading to earlier menopause and reduced fertility window.